Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions
Authors
Keywords
-
Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 23, Issue 32, Pages 5875
Publisher
Baishideng Publishing Group Inc.
Online
2017-08-28
DOI
10.3748/wjg.v23.i32.5875
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine
- (2017) Volker Kunzmann et al. PANCREAS
- Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters
- (2017) Patricia Dauer et al. PANCREATOLOGY
- A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel
- (2017) Ana Mato-Berciano et al. Oncotarget
- Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer
- (2017) Jane Cullis et al. Cancer Immunology Research
- FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer
- (2016) Howard Safran et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Positron emission tomography response evaluation from a randomized phase III trial of weeklynab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas
- (2016) R. K. Ramanathan et al. ANNALS OF ONCOLOGY
- CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weeklynab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
- (2016) E. G. Chiorean et al. ANNALS OF ONCOLOGY
- Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in unresectable or borderline resectable pancreatic adenocarcinoma
- (2016) M. Reni et al. ANNALS OF ONCOLOGY
- Pancreatic cancer chemoradiotherapy
- (2016) Thomas B. Brunner et al. BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
- Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer
- (2016) N V Rajeshkumar et al. BRITISH JOURNAL OF CANCER
- Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
- (2016) E Gabriela Chiorean et al. BRITISH JOURNAL OF CANCER
- Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma
- (2016) Michele Reni et al. BRITISH JOURNAL OF CANCER
- A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study
- (2016) Steven J. Cohen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
- (2016) Hideki Ueno et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)
- (2016) David Goldstein et al. EUROPEAN JOURNAL OF CANCER
- S-1 plusnab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model
- (2016) Masaya Suenaga et al. JOURNAL OF SURGICAL ONCOLOGY
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts
- (2016) H. Kim et al. MOLECULAR CANCER THERAPEUTICS
- Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models
- (2016) Jian-Ang Li et al. PANCREAS
- Adjuvant and Neoadjuvant Therapy for Resectable Pancreatic and Periampullary Cancer
- (2016) Stephanie M. Kim et al. SURGICAL CLINICS OF NORTH AMERICA
- FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer
- (2016) Chiara Caparello et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Epidemiology of pancreatic cancer
- (2016) Milena Ilic et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models
- (2016) Niranjan Awasthi et al. Oncotarget
- Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) M. Ducreux et al. ANNALS OF ONCOLOGY
- A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial
- (2015) Jean-Baptiste Bachet et al. BMC CANCER
- The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival
- (2015) Daniel Delitto et al. BMC CANCER
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer
- (2015) Jessica D Sun et al. CANCER BIOLOGY & THERAPY
- Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration
- (2015) Nianhang Chen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
- (2015) M. Hidalgo et al. CLINICAL CANCER RESEARCH
- Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma
- (2015) Daneng Li et al. Clinical Colorectal Cancer
- 2335 Analysis of activity, efficacy and safety of first line Nab Paclitaxel (Nab-P) and Gemcitabine (G) in advanced pancreatic cancer (APDAC) frail and elderly patients (pts)
- (2015) G. Giordano et al. EUROPEAN JOURNAL OF CANCER
- Nab-paclitaxel (Nab-P) and gemcitabine (G) as first-line chemotherapy (CT) in advanced pancreatic cancer (APDAC) elderly patients (pts): A “real-life” study.
- (2015) Guido Giordano et al. JOURNAL OF CLINICAL ONCOLOGY
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer
- (2015) J. Tabernero et al. ONCOLOGIST
- Metastatic pancreatic cancer: Is there a light at the end of the tunnel?
- (2015) Vanja Vaccaro WORLD JOURNAL OF GASTROENTEROLOGY
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- Taxanes
- (2014) E. Gabriela Chiorean et al. ANTI-CANCER DRUGS
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
- (2014) Helmut Oettle et al. JOURNAL OF CLINICAL ONCOLOGY
- Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin-Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma
- (2014) V. Gonzalez-Villasana et al. MOLECULAR CANCER THERAPEUTICS
- Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer
- (2014) Erkut Borazanci et al. Expert Review of Gastroenterology & Hepatology
- Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
- (2013) R Alvarez et al. BRITISH JOURNAL OF CANCER
- Stromal expression of SPARC in pancreatic adenocarcinoma
- (2013) Cindy Neuzillet et al. CANCER AND METASTASIS REVIEWS
- Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer
- (2013) Dong-sheng Zhang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Tumour–stroma interactions in pancreatic ductal adenocarcinoma: Rationale and current evidence for new therapeutic strategies
- (2013) V. Heinemann et al. CANCER TREATMENT REVIEWS
- Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer
- (2013) N. Awasthi et al. CARCINOGENESIS
- SPARC independent drug delivery and antitumour effects ofnab-paclitaxel in genetically engineered mice
- (2013) Albrecht Neesse et al. GUT
- nab-Paclitaxel mechanisms of action and delivery
- (2013) Denise A. Yardley JOURNAL OF CONTROLLED RELEASE
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Challenges in Development of Nanoparticle-Based Therapeutics
- (2012) Neil Desai AAPS Journal
- Targeting the Cancer-Stroma Interaction: A Potential Approach for Pancreatic Cancer Treatment
- (2012) Xuqi Li et al. CURRENT PHARMACEUTICAL DESIGN
- nab -Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer
- (2012) Kristopher K. Frese et al. Cancer Discovery
- Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
- (2011) Uwe Pelzer et al. EUROPEAN JOURNAL OF CANCER
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stromal Depletion Goes on Trial in Pancreatic Cancer
- (2010) K. Garber JNCI-Journal of the National Cancer Institute
- Pancreatic Cancer
- (2010) Manuel Hidalgo NEW ENGLAND JOURNAL OF MEDICINE
- Significance of M2-Polarized Tumor-Associated Macrophage in Pancreatic Cancer
- (2009) Hiroshi Kurahara et al. JOURNAL OF SURGICAL RESEARCH
- SPARC: a matricellular regulator of tumorigenesis
- (2009) Shanna A. Arnold et al. Journal of Cell Communication and Signaling
- The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host
- (2008) Osvaldo L. Podhajcer et al. CANCER AND METASTASIS REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search